Catecholamine receptor

Catecholamine receptors are a broad class of G protein-coupled receptors (GPCRs) that respond to the endogenous catecholamines dopamine, norepinephrine, and epinephrine (StatPearls, NBK507716). This category is divided into two primary systems: the adrenergic receptors (alpha-1, alpha-2, beta-1, beta-2, and beta-3) and the dopamine receptors (D1, D2, D3, D4, and D5) (IUPHAR/BPS Guide to Pharmacology). These receptors are essential for the regulation of the sympathetic nervous system and central neurotransmission, controlling vital functions such as heart rate, vascular resistance, and airway tone (PubMed, PMID: 30252301). In the central nervous system, they mediate complex behaviors including reward, motor control, and cognition, making them key factors in the pathology of Parkinson's disease, schizophrenia, and ADHD (NIH, 2022). Consequently, they are among the most significant therapeutic targets in pharmacology, with applications ranging from emergency medicine and cardiology to psychiatry and neurology (PubChem). Drugs acting on these receptors include a wide variety of agonists and antagonists that modulate intracellular second messenger systems like cyclic AMP and inositol trisphosphate (UniProt).

Other names

AdrenoceptorAdrenergic receptorDopamine receptorAdrenoreceptorCatecholaminergic receptor

Drugs targeting catecholamine receptors function as agonists or antagonists that modulate G protein-coupled signaling pathways, specifically affecting adenylyl cyclase activity to alter cAMP levels or activating phospholipase C to increase intracellular calcium (StatPearls, NBK507716; IUPHAR/BPS).